Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 6 peer-reviewed journal articles Updated
Pediatric Neurology

The Horizon of Hope: Clinical Trials and Gene Therapy

At a Glance

Experimental gene therapies, such as MYR-101 and BBP-812, are currently in clinical trials for Canavan disease. These treatments use a modified virus to deliver a healthy ASPA gene to the brain, aiming to lower toxic NAA levels and improve myelination in affected children.

For the first time in the history of Canavan disease, research has moved from the laboratory to the bedside. While there is not yet a “cure,” several gene therapy trials are currently underway, offering a window of hope for families [1][2]. These treatments are still experimental, meaning they are being tested for safety and effectiveness and are not yet available as standard medical care [3][1].

The Goal of Gene Therapy

In Canavan disease, the ASPA gene is faulty, so it cannot make the enzyme needed to break down NAA [4]. Gene replacement therapy aims to solve this by delivering a “working” copy of the gene directly to the brain cells [1].

  • The Delivery Truck (Vector): Scientists use a harmless, modified virus called an Adeno-Associated Virus (AAV) to carry the healthy gene into the cells [1][T-8QDTKNBK].
  • The Target: In newer trials, the goal is to get this gene into the oligodendrocytes—the specific cells that create and maintain the brain’s protective white matter (myelin) [T-B86IOUUS][5].

Recent Trial Highlights

Two major gene therapy programs have reported encouraging early results in children with the classic infantile form of the disease.

1. MYR-101 (rAAV-Olig001-ASPA)

This therapy is administered directly into the brain via a one-time surgical procedure [T-B86IOUUS].

  • Reduced NAA: Interim data from Phase 1/2 trials have shown a significant reduction in NAA levels in the brain and cerebrospinal fluid [1][2].
  • Increased Myelination: Brain imaging has shown early evidence of improved myelination (the growth of white matter) [1].
  • Developmental Gains: Some children in the study have shown improvements in motor skills and alertness beyond what is typically seen in the natural progression of the disease [1].

2. BBP-812 (CANaspire Trial)

This approach uses a different delivery method (AAV9) and is also being tested in infants and young children [T-8QDTKNBK]. Like MYR-101, it aims to restore the missing enzyme and lower the toxic buildup of NAA in the brain [T-8QDTKNBK].

Other Research Directions

Beyond gene replacement, researchers are looking at other ways to protect the brain:

  • Metabolic Inhibitors: Some studies are looking at ways to block the production of NAA before it can build up. This involves targeting an enzyme called NAT8L [4][6].
  • Natural History Studies: Programs like the Myelin Disorders Biorepository Project collect data and samples from children with Canavan disease to help scientists better understand how the disease progresses, which is essential for designing future treatments [T-8D6TTHS2].

A Note of Caution

While the results from these early trials are promising, they are still in the Phase 1/2 stage [1][T-8QDTKNBK]. This means they are primarily designed to see if the treatment is safe and to find the right dose. Participating in a trial is a significant decision that involves surgery and long-term follow-up [T-B86IOUUS]. It is vital to discuss these options with a specialized pediatric neurologist to determine if your child meets the strict eligibility criteria, which are often based on age and genetic mutation type [T-B86IOUUS][T-8QDTKNBK].

Common questions in this guide

How does gene therapy work for Canavan disease?
Gene therapy uses a harmless, modified virus called an AAV vector to deliver a working copy of the ASPA gene directly into brain cells. This aims to restore the missing enzyme needed to break down NAA and promote the growth of protective white matter.
What are the MYR-101 and BBP-812 clinical trials?
MYR-101 and BBP-812 are two experimental gene replacement therapies currently in Phase 1/2 trials for children with Canavan disease. Early data suggests these treatments may help reduce toxic NAA levels in the brain and improve developmental milestones.
Is gene therapy available as a standard treatment for Canavan disease?
No, gene therapies for Canavan disease are currently experimental and only available through participation in clinical trials. These early-stage trials are primarily focused on determining the safety, correct dosage, and initial effectiveness of the treatments.
Are there other treatments being researched besides gene therapy?
In addition to gene replacement, scientists are investigating metabolic inhibitors that target the NAT8L enzyme. The goal of this approach is to block the production of NAA before it can build up to toxic levels in the brain.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which gene therapy clinical trials is my child currently eligible for based on their age and mutation?
  2. 2.Can you explain the difference between the 'intracranial' delivery and 'intravenous' delivery used in current gene therapy trials?
  3. 3.What were the specific outcomes (like reduced NAA or improved motor scores) for children in my child's age group in recent study reports?
  4. 4.If we decide not to pursue a gene therapy trial right now, what other research-based metabolic treatments should we be aware of?
  5. 5.What are the long-term risks or potential side effects of using AAV vectors in a child's brain?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (6)
  1. 1

    Oligodendrocyte-targeted adeno-associated virus gene therapy for Canavan disease in children: a phase 1/2 trial.

    Leone P, Lober RM, Francis J, et al.

    Nature medicine 2025; (31(11)):3772-3779 doi:10.1038/s41591-025-03919-w.

    PMID: 40957959
  2. 2

    Adeno-associated virus-mediated gene therapy in a patient with Canavan disease using dual routes of administration and immune modulation.

    Corti M, Byrne BJ, Gessler DJ, et al.

    Molecular therapy. Methods & clinical development 2023; (30()):303-314 doi:10.1016/j.omtm.2023.06.001.

    PMID: 37601414
  3. 3

    Pathophysiology and Treatment of Canavan Disease.

    Pleasure D, Guo F, Chechneva O, et al.

    Neurochemical research 2020; (45(3)):561-565 doi:10.1007/s11064-018-2693-6.

    PMID: 30535831
  4. 4

    Development of bisubstrate analog inhibitors of aspartate N-acetyltransferase, a critical brain enzyme.

    Mutthamsetty V, Dahal GP, Wang Q, Viola RE

    Chemical biology & drug design 2020; (95(1)):48-57 doi:10.1111/cbdd.13586.

    PMID: 31260162
  5. 5

    Renewal of oligodendrocyte lineage reverses dysmyelination and CNS neurodegeneration through corrected N-acetylaspartate metabolism.

    Lotun A, Li D, Xu H, et al.

    Progress in neurobiology 2023; (226()):102460 doi:10.1016/j.pneurobio.2023.102460.

    PMID: 37149081
  6. 6

    Cellular and molecular mechanisms of aspartoacylase and its role in Canavan disease.

    Grønbæk-Thygesen M, Hartmann-Petersen R

    Cell & bioscience 2024; (14(1)):45 doi:10.1186/s13578-024-01224-6.

    PMID: 38582917

This page provides informational content regarding experimental gene therapies and clinical trials for Canavan disease. It does not replace professional medical advice; always consult a specialized pediatric neurologist regarding your child's treatment and trial eligibility.

Get notified when new evidence is published on Canavan disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.